1 / 9

Sofosbuvir-Velpatasvir in Decompensated HCV Cirrhosis ASTRAL-4

Explore the efficacy & safety of Sofosbuvir-Velpatasvir in Decompensated HCV Cirrhosis with participants who are treatment-naïve & experienced. Study features, results by genotype, MELD score changes, adverse events, and conclusions.

credmon
Download Presentation

Sofosbuvir-Velpatasvir in Decompensated HCV Cirrhosis ASTRAL-4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentNaïve & Experienced Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4 Curry MP, et al. N Engl J Med. 2015;373:2618-28.

  2. Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4: Study Features Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.

  3. Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4: Study Design 0 12 36 24 Week Treatment-naïve & experiencedGT 1, 2, 3, 4, 6 CTP Class B SOF-VEL N=90 SVR12 SOF-VEL + RBV SVR12 N=87 SOF-VEL SVR12 N=90 Abbreviations: SOF-VEL = sofosbuvir-velpatasvir; RBV = ribavirin Drug DosingSofosbuvir-velpatasvir (400/100 mg): fixed-dose combination; one pill once dailySofosbuvir: 400 mg once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.

  4. Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4: Participants Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.

  5. Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4: Participants Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.

  6. Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4: Results ASTRAL-4: SVR12 Results by Genotype 75/90 82/87 77/90 60/68 65/68 65/71 7/14 11/13 6/12 8/8 6/6 6/7 Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.

  7. Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4: Change in MELD Scores on Treatment 27% Worsened 52% Improved Baseline MELD <15 n=208 n= Change in MELD 84% Improved 8% Worsened Baseline MELD >15 n=26 n= Change in MELD Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.

  8. Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4: Adverse Events Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.

  9. Sofosbuvir-Velpatasvir in Decompensated HCV CirrhosisASTRAL-4: Conclusions Source: Curry MP, et al. N Engl J Med. 2015;373:2618-28.

More Related